Recent application of immunotherapy in clinical oncology revolutionized our management of advanced human cancers. Check point inhibitors targeting CTLA4 and PD-1/PD-L1 axis are immunotherapeutic agents currently available to treat a variety of cancers. However. a novel therapeutic approach is needed to further improve patient outcome with these agents. https://www.markymarkscott.com/product-category/11n/